Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study on Early Lyme Neuroborreliosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00910533
Recruitment Status : Unknown
Verified May 2017 by Franc Strle, University Medical Centre Ljubljana.
Recruitment status was:  Recruiting
First Posted : June 1, 2009
Last Update Posted : October 16, 2018
Sponsor:
Information provided by (Responsible Party):
Franc Strle, University Medical Centre Ljubljana

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to determine clinical course and the sequelae of early Lyme neuroborreliosis after treatment with ceftriaxone.

Condition or disease Intervention/treatment Phase
Nervous System Lyme Borreliosis Drug: ceftriaxone Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Clinical and Microbiological Parameters in Patients With Early Lyme Neuroborreliosis
Study Start Date : January 1, 2009
Estimated Primary Completion Date : December 31, 2018
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lyme Disease

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Early Lyme neuroborreliosis patients Drug: ceftriaxone
ceftriaxone 2 g od i.v. for 14 days
No Intervention: control subjects
Control subjects without a history of Lyme borreliosis.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Objective sequelae and post-treatment subjective symptoms in patients treated with ceftriaxone for early Lyme neuroborreliosis [ Time Frame: 1 year follow-up ]

Secondary Outcome Measures :
  1. Comparison of subjective symptoms between patients treated with ceftriaxone for early Lyme neuroborreliosis and control subjects without a history of Lyme borreliosis [ Time Frame: 1 year follow-up ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • erythema migrans within 4 months before neurologic involvement and pleocytosis in patients >15 years old

Exclusion Criteria:

  • pregnancy
  • lactation
  • history of adverse reaction to a beta-lactam antibiotic
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00910533


Contacts
Layout table for location contacts
Contact: Dasa Stupica, MD +38615222110 cerar.dasa@gmail.com
Contact: Franc Strle, MD +38615222110 franc.strle@kclj.si

Locations
Layout table for location information
Slovenia
UMC Ljubljana, Department of Infectious Diseases Recruiting
Ljubljana, Slovenia, 1525
Contact: Dasa Stupica, MD    +386 1 522 2110    cerar.dasa@gmail.com   
Contact: Franc Strle, MD    +386 1 5222610    franc.strle@kclj.si   
Principal Investigator: Dasa Stupica, M.D., PhD         
Sub-Investigator: Katarina Ogrinc, M.D., PhD         
Sub-Investigator: Petra Bogovic, MD         
Sub-Investigator: Eva Ruzic-Sabljic, M.D., PhD         
Sub-Investigator: Tjasa Cerar, PhD         
Sponsors and Collaborators
University Medical Centre Ljubljana
Investigators
Layout table for investigator information
Study Chair: Franc Strle, MD UMC Ljubljana
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Franc Strle, M.D., PhD, University Medical Centre Ljubljana
ClinicalTrials.gov Identifier: NCT00910533    
Other Study ID Numbers: LNB-0509
First Posted: June 1, 2009    Key Record Dates
Last Update Posted: October 16, 2018
Last Verified: May 2017
Keywords provided by Franc Strle, University Medical Centre Ljubljana:
Lyme neuroborreliosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Lyme Disease
Lyme Neuroborreliosis
Borrelia Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Spirochaetales Infections
Tick-Borne Diseases
 Central Nervous System Bacterial Infections
Central Nervous System Infections
Central Nervous System Diseases
Nervous System Diseases
Ceftriaxone
Anti-Bacterial Agents
Anti-Infective Agents